StockNews.AI

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE

StockNews.AI • 2 days

RARE
High Materiality10/10

Information

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of inves...

Original source

AI Summary

Pomerantz LLP is investigating Ultragenyx for potential securities fraud involving setrusumab trials. Following failed primary endpoints in clinical studies, the company saw its stock drop significantly to $0.28, despite meeting secondary study goals.

Trading Thesis

In light of the investigation and stock price drop, RARE may pose a risky investment.

Market-Moving

  • Pomerantz LLP investigations can lead to class-action lawsuits affecting stock performance.
  • Failed drug trials often lead to severe investor confidence drops.
  • Heightened scrutiny may discourage future investments in Ultragenyx.
  • Continued regulatory and legal challenges could hamper recovery efforts.

Key Facts

  • Ultragenyx's stock price fell from $2.34 to $0.28 on Dec. 29, 2025.
  • Two Phase 3 studies did not meet primary efficacy endpoints.
  • Secondary endpoints showed improvements in bone mineral density.
  • Pomerantz LLP is a well-known securities litigation firm.
  • The professional undertaking follows allegations of securities fraud.

Companies Mentioned

  • Ultragenyx Pharmaceutical Inc. (RARE): Under investigation for potential fraud impacting investor confidence.

Corporate Developments

This situation falls under corporate governance issues due to the ongoing investigation and potential legal ramifications affecting shareholder value.

FAQ

Why Very Bearish?

Historical examples show that failed drug trials lead to substantial stock declines, particularly if fraud is investigated.

How important is it?

The investigation and resulting stock plunge highlight critical governance issues that could affect overall market perception.

Why Short Term?

Investor sentiment may decline rapidly due to ongoing investigations and stock performance issues.

Related Companies

RARE

Investor Alert: Pomerantz Law Firm Investigates Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE)

New York, January 6, 2026 (GLOBE NEWSWIRE) — Pomerantz LLP is currently investigating potential claims on behalf of investors in Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). This investigation centers on allegations that Ultragenyx, along with certain officers and/or directors, may have engaged in securities fraud or other unlawful business practices.

Details of the Investigation

Investors concerned about their investment in RARE are encouraged to reach out to Danielle Peyton at newaction@pomlaw.com or by phone at 646-581-9980, ext. 7980. The firm is collecting information from investors as part of its inquiry into the company's activities.

Impact of Recent Phase 3 Study Results

On December 29, 2025, during pre-market hours, Ultragenyx announced the results from two Phase 3 studies regarding setrusumab, a treatment aimed at addressing conditions related to bone metabolism. The results from these studies revealed that:

  • Neither study achieved statistical significance in the primary endpoints related to the reduction in annualized clinical fracture rate compared to placebo or bisphosphonates.
  • However, both studies successfully met their secondary endpoints, demonstrating improvements in bone mineral density against comparators, with strong statistical significance.
  • No alterations in the safety profile of the drug were noted during the studies.

Following this announcement, the stock price of Ultragenyx plummeted by $2.02 per share, marking an 87.64% decline to close at $0.28 per share on the same day.

Pomerantz LLP: A Leader in Class Action Litigation

Pomerantz LLP, a prominent law firm with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, has built a strong reputation in the fields of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the firm has been fighting for the rights of victims of securities fraud and corporate misconduct for over 85 years.

Historically, Pomerantz has successfully recovered numerous multimillion-dollar damages awards on behalf of class members, reinforcing its status as a leader in this area of law. For more information, visit www.pomlaw.com.

Contact Information

For further details regarding the investigation or to discuss potential claims, investors are urged to contact:

Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980

Note: This communication is considered attorney advertising. Past results do not guarantee similar outcomes.

Related News